THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [3.9] ID: TIP-MED-000009

Carvedilol

Active Ingredient / Scientific Identity: Carvedilol • Class: Non-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antioxidant Vasodilator

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Carvedilol ([3.9] | ID: TIP-MED-000009) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/3-9-carvedilol/
Generic / Entity NameCarvedilol ([3.9])
Verified Indian Brands / RefAldactone (RPG Life Sciences)
Pharmacological ClassNon-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antioxidant Vasodilator
Available Dosage FormsOral Immediate-Release Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg; Controlled-Release Capsules/Tablets: 10 mg,
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Eliminated primarily via biliary/hepatic route (<2% unchanged in urine); no routine dose reduction required in CKD, ma
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Carvedilol (TIP-MED-000009, Reference Code [3.9]) is classified under Cardiovascular & Antithrombotic Medicines (Ch 03) as a Non-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antioxidant Vasodilator. Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Aldactone (RPG Life Sciences)
Representative Indian Market Examples (Edition 2.7 Ch 03 [3.9], p. 25): Cardivas (Sun Pharma), Carloc (Cipla), Carca (Intas), Carvedil (Alkem) — also available as Carvedilol CR 10 mg, 20 mg — Strengths & Dosage Forms: Oral Immediate-Release Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg; Controlled-Release Capsules/Tablets: 10 mg, 20 mg, 40 mg
Dosage Forms & Available Strengths:
Oral Immediate-Release Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg; Controlled-Release Capsules/Tablets: 10 mg, 20 mg, 40 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Non-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antioxidant Vasodilator acting on target receptor/enzyme pathways in Cardiovascular & Antithrombotic Medicines (Ch 03): clinical efficacy is mediated via Non-Selective Beta-1/Beta-2 and Alpha-1 Adrenergic Blocker; Antioxidant Vasodilator for Chronic heart failure with reduced ejection fraction (HFrEF—reduces mortality); left ventricular dysfunction post-myocardial infarction; essential hypertension; portal hypertension / oesophageal variceal prophylaxis in cirrhosis..

4. Therapeutic Indications & Evidence-Supported Uses

  • Chronic heart failure with reduced ejection fraction (HFrEF—reduces mortality)
  • left ventricular dysfunction post-myocardial infarction
  • essential hypertension
  • portal hypertension / oesophageal variceal prophylaxis in cirrhosis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Heart Failure: Start at 3.125 mg twice daily with food for 2 weeks; double every 2 weeks as tolerated to 6.25 mg BD, 12.5 mg BD, up to target 25 mg BD. Hypertension: Start 6.25 mg BD, max 25 mg BD. Follow physician titration.

Administration & Meal Timing: Must be taken WITH food (taking with meals slows the rate of absorption without reducing total bioavailability, significantly reducing the risk of postural hypotension). | Twice daily with breakfast and dinner (for IR tablets); once daily in the morning with breakfast for CR formulations.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Eliminated primarily via biliary/hepatic route (<2% unchanged in urine); no routine dose reduction required in CKD, making it the preferred beta-blocker in CKD/dialysis patients with HFrEF. Hepatic: Contraindicated in severe hepatic dysfunction / Child-Pugh Class C cirrhosis.
Elimination & Renal Adjustment:
Renal: Eliminated primarily via biliary/hepatic route (<2% unchanged in urine); no routine dose reduction required in CKD, making it the preferred beta-blocker in CKD/dialysis patients with HFrEF. Hepatic: Contraindicated in severe hepatic dysfunction / Child-Pugh Class C cirrhosis.
Hepatic Impairment Considerations:
Renal: Eliminated primarily via biliary/hepatic route (<2% unchanged in urine); no routine dose reduction required in CKD, making it the preferred beta-blocker in CKD/dialysis patients with HFrEF. Hepatic: Contraindicated in severe hepatic dysfunction / Child-Pugh Class C cirrhosis.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in bronchial asthma or bronchospastic COPD (due to non-selective Beta-2 blockade), severe hepatic impairment, 2nd/3rd degree AV block, severe bradycardia, and decompensated NYHA Class IV heart failure requiring IV inotropes.

Key Clinical Precautions: Renal: Eliminated primarily via biliary/hepatic route (<2% unchanged in urine); no routine dose reduction required in CKD, making it the preferred beta-blocker in CKD/dialysis patients with HFrEF. Hepatic: Contraindicated in severe hepatic dysfunction / Child-Pugh Class C cirrhosis.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Postural dizziness / orthostatic hypotension (alpha-1 blockade, especially after initial doses or titration), bradycardia, transient fluid retention during up-titration, fatigue, diarrhoea.
  • Severe bronchospasm in reactive airway disease, syncope, complete AV block, acute decompensation of heart failure, masked hypoglycaemia.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Increases serum digoxin levels by 15–20% (P-gp inhibition)
  • CYP2D6 inhibitors (fluoxetine, paroxetine, amiodarone) increase R/S-carvedilol levels
  • Rifampicin reduces carvedilol levels by 70%
  • Additive bradycardia with diltiazem, verapamil, ivabradine, and clonidine

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Always take carvedilol with breakfast and dinner—never on an empty stomach, or you may feel dizzy when standing up. In heart failure, explain that the medicine strengthens the heart over months, even if mild tiredness occurs during the first 1–2 weeks of dose increase.
  • Meal & Clock Timing Instruction: Must be taken WITH food (taking with meals slows the rate of absorption without reducing total bioavailability, significantly reducing the risk of postural hypotension). (Twice daily with breakfast and dinner (for IR tablets); once daily in the morning with breakfast for CR formulations.)
  • Missed Dose Protocol: Take with food as soon as remembered if within 4–6 hours; if closer to the next dose, skip and resume normal schedule. Never double the dose.
  • Geriatric Dispensing Pearl: Alpha-1 blocking property causes higher rates of orthostatic dizziness than bisoprolol or metoprolol in the elderly. Counsel patients to sit on the edge of the bed for 1 minute before standing, and verify they do not have asthma/wheezing.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Immediate-Release Tablets: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg; Controlled-Release Capsules/Tablets: 10 mg, 20 mg, 40 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 03 [3.9] (p. 25)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/3-9-carvedilol/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.